- Home
- GBIO vs LANV Comparison
GBIO vs LANV Comparison
Compare GBIO & LANV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- LANV
- Stock Information
- Founded
- GBIO 2016
- LANV 2015
- Country
- GBIO United States
- LANV China
- Employees
- GBIO N/A
- LANV N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- LANV Blank Checks
- Sector
- GBIO Health Care
- LANV Finance
- Exchange
- GBIO Nasdaq
- LANV Nasdaq
- Market Cap
- GBIO 64.8M
- LANV 219.4M
- IPO Year
- GBIO 2020
- LANV N/A
- Fundamental
- Price
- GBIO $0.88
- LANV $1.85
- Analyst Decision
- GBIO Strong Buy
- LANV
- Analyst Count
- GBIO 2
- LANV 0
- Target Price
- GBIO $6.50
- LANV N/A
- AVG Volume (30 Days)
- GBIO 581.0K
- LANV 92.6K
- Earning Date
- GBIO 03-05-2025
- LANV 02-19-2025
- Dividend Yield
- GBIO N/A
- LANV N/A
- EPS Growth
- GBIO N/A
- LANV N/A
- EPS
- GBIO N/A
- LANV N/A
- Revenue
- GBIO $18,582,000.00
- LANV $409,961,427.00
- Revenue This Year
- GBIO $212.74
- LANV N/A
- Revenue Next Year
- GBIO N/A
- LANV $10.45
- P/E Ratio
- GBIO N/A
- LANV N/A
- Revenue Growth
- GBIO 514.08
- LANV N/A
- 52 Week Low
- GBIO $0.75
- LANV $0.91
- 52 Week High
- GBIO $4.65
- LANV $3.78
- Technical
- Relative Strength Index (RSI)
- GBIO 28.66
- LANV 46.31
- Support Level
- GBIO $0.85
- LANV $1.69
- Resistance Level
- GBIO $1.01
- LANV $2.09
- Average True Range (ATR)
- GBIO 0.12
- LANV 0.24
- MACD
- GBIO 0.00
- LANV -0.04
- Stochastic Oscillator
- GBIO 7.50
- LANV 25.97
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About LANV Lanvin Group Holdings Limited
Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.